Reinforced Sputnik-V Induced Spike Protein Antibody Levels in Pakistan: An Edge of Sputnik-V Over Sinopharm and SinoVac as Commercially Available COVID-19 Vaccines
| Author | Umar Saeed | en |
| Author | Rizwan Uppal | en |
| Author | Aftab Ahmad Khan | en |
| Author | Rehan Uppal | en |
| Author | Zahra Zahid Piracha | en |
| Author | Sara Rizwan Uppal | en |
| Orcid | Umar Saeed [0000-0002-9740-0371] | en |
| Orcid | Zahra Zahid Piracha [0000-0001-8973-9773] | en |
| Issued Date | 2022-08-31 | en |
| Abstract | Background: Despite several challenges, the SARS-CoV-2 pandemic is still not over. Rapid mass-scale immunization is critical to prevent further COVID-19-associated deaths. Objectives: Herein, we aimed to evaluate the rapid ramp-up effects of spike antibodies in response to Sputnik V, Sinopharm, and SinoVac first dose administration in the general public of Pakistan. Methods: A cross-sectional study was conducted on 2000 participants to examine Sputnik V, Sinopharm, and SinoVac first dose effects 21 days post-administration. From 1200 real-time PCR negative subjects, the samples were subjected to SARS-CoV-2 spike antibody levels using electro-chemiluminescence immunoassay (ECLIA) (Elecsys, # 09289267190 Roche, USA). Results: SARS-CoV-2 spike protein positivity was detected highest at 87% among participants receiving SputnikV with SARS-CoV-2 spike protein antibodies > 1.5 AU/mL compared to 47.6% and 25% in individuals receiving Sinopharm and SinoVac, respectively. Also, 36.04% of the Sputnik-administered individuals depicted antibody levels > 250 AU/mL. Of the participants, 55% had a previous history of COVID-19. Also, 14.86%, 4.76%, and 0% of the SputnikV, Sinopharm, and SinoVac administered subjects showed antibodies > 100 AU/mL, respectively, while > 25 AU/mL antibodies were found in 10.70% of SputnikV, 19.04% of Sinopharm and 10.71% of SinoVac administered individuals. Moreover, > 1.5 - 2.5 AU/mL antibodies levels were found in 25.10%, 23.80%, and 14.28% of participants with SputnikV, Sinopharm, and SinoVac administered vaccines, respectively. The antibody titers of < 1.5 AU/mL were detected among 13.30%, 52.38%, and 46.42% of subjects administered with SputnikV, Sinopharm, and SinoVac vaccines, respectively. Conclusions: Even before administrating the second booster dose of SputnikV, a significantly higher number of patients depicted rapid ramp-up of SARS-CoV-2 specific spike antibodies, which can significantly contribute to rapid mass-immunization. Despite all challenges, persistent antibody plateau monitoring is critical to attaining humoral immunity against SARS-CoV-2 infections. | en |
| DOI | https://doi.org/10.5812/jjm-128933 | en |
| URI | https://brieflands.com/journals/jjm/articles/128933 | en |
| Keyword | SARS-CoV-2 | en |
| Keyword | COVID-19 Vaccines | en |
| Keyword | Sputnik V | en |
| Keyword | Sinopharm | en |
| Keyword | SinoVac | en |
| Keyword | Antibody | en |
| Publisher | Brieflands | en |
| Title | Reinforced Sputnik-V Induced Spike Protein Antibody Levels in Pakistan: An Edge of Sputnik-V Over Sinopharm and SinoVac as Commercially Available COVID-19 Vaccines | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jjm-15-8-128933.pdf
- Size:
- 244.14 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF